price month
 close
updat thought earn insight
follow call decreas tp
impact co-pay accumul program increas area focu
report strong beat rais quarter driven mostli
surprisingli strong hcv sale also increas fy ep guidanc
almost half ep increas cent
cent driven announc dutch auction
tender offer compani announc today schedul start
may remaind driven oper chang
notabl increas global hcv sale guidanc greater
also lower us humira sale forecast say
ad conservat due new co-pay accumul
program even though see signific impact
program yet vocal role co-pay accumul
program may play headwind compani one
risk given import humira compani base
statement prepar remark well question
ask confer call see grow concern may
materi pleas refer theme catalyst
team detail thought co-pay accumul
program spoke team follow confer call
incorpor note well comment co-pay
accumul program report along takeaway
follow call
valuat risk target price decreas
maintain neutral rate ep chang
target price
blend dcf rel price-to-earnings valuat main
risk call includ stronger/weak expect humira sale
unexpect pipelin successes/failur
valuat metric
number share
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
opportun speak member team follow
confer call gain addit clariti dynam around certain product
well bake updat expect around fy
summar compani answer question
done earlier year prior new author
year year remaind
driver increas ep guidanc
cent due buy-back
cent due oper chang
detail dutch auction tender
execut rapidli vs asr sever month
complet fairli short order within
addit color come day investor tender
fy vs prior sale
fy approach vs prior sale
fy vs prior
small chang due product mix
us humira approach y/i ex-u approach
fy us ex-u approach vs prior
fy us ww greater unchang
patient group share plan lobbi
educ import patient avoid kind program
impact accumul program
expect impact broad rang specialti program humira
impact mitig program seen net sale
stanc co-pay accumul program
conserv stanc co-pay cost associ cost accumul program
program havent materi impact continu monitor
quantifi effect co-pay program
humira patient volum
think program bad polici esp patient specialti med
impact doubt big impact
built addit expens amount patient popul
patient higher averag deduct prior year common
chronic ill patient comorbid medic
expens year may get deduct month vs month
want lose patient month within updat co-pay
program flexibl go higher
sure yet whether itll seen think appropri model
experi program
enough perform busi watch goe deliv
except perform rais guidanc need
think co-pay accumul program could
like risankizumab
want disrupt larg number
heard descript mani program program
may similar
gener design rais co-pay higher level
typic high-deduct plan higher co-pay higher level
respons patient
averag co-pay high
typic co-pay would closer get
much higher co-pay insur compani take greater
specif product base experi
bad polici appropri put level burden
patient need product
rel small percentag patient far
percentag popul co-pay
accumul benefit
base intern data patient high-deduct plan
co-pay accumul associ
bring overal humira popul
option patient select program
feedback patients- extrem unhappi polici
think patient flexibl signific expens associ
chronic condit exit program
may lower cost premium up-front big co-pay difficult
manag
could see percentag come
certain employ dont elect option patient choic
impact far go measur
sale
net interest incom
us million unless otherwis state
product sold ex-amort
tax earn
average share outstand
dilut ep oper
us million unless otherwis state
rova-t acquir stemcentrx
pipelin total sale
research-bas pharmaceut compani broad
sustain portfolio market-lead proprietari
pharmaceut biolog sold world-wide
price apr rate neutral target price analyst vamil divan
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
cash-flow financ activ
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky valuat base greater sale
humira imbruvica market product compar
current base case assumpt blue sky valuat base
dcf driven wacc termin valu
grey sky valuat base lower sale humira
imbruvica market product compar current base
case assumpt grey sky valuat base dcf driven
wacc termin valu
 close
compani mention price
